Large Reperfused ST-Elevation Myocardial Infarction Clinical Trial
— CATCH-AMIOfficial title:
CXCR4 AnTagonism for Cell Mobilisation and Healing in Acute Myocardial Infarction (CATCH-AMI). A Phase IIa, Double-Blind, Placebo-Controlled, Randomised, Multi-centre Study of POL6326, a CXCR4 Antagonist, in Patients With Large Reperfused ST Elevation Myocardial Infarction
The purpose of this study is to investigate the effects of POL6326 (CXCR4 antagonist) as a stem cell mobilizing agent, on cardiac function and infarct size and on safety and tolerability, in patients with reperfused ST-Elevation Myocardial Infarction (STEMI).
| Status | Completed |
| Enrollment | 120 |
| Est. completion date | June 2016 |
| Est. primary completion date | October 2015 |
| Accepts healthy volunteers | No |
| Gender | Both |
| Age group | 18 Years to 80 Years |
| Eligibility |
Inclusion Criteria: 1. Patients with symptoms suggestive of an acute MI with ST-segment elevation or new left bundle-branch block and a rise or fall in cardiac necrosis markers. 2. Patients must be scheduled to undergo coronary angiography for the purposes of primary PCI (percutaneous coronary intervention) culminating in successful stent implantation. 3. Age between 18 and 80 years. Male and WOCBP (women of child bearing potential) willing to use highly effective methods of contraception from the time of first dose until 3 months after the last dose of the drug. 4. Markedly reduced LVEF at baseline cardiac MRI. 5. No previous occurrence of Myocardial Infarction. 6. Estimated glomerular filtration rate (eGFR) equal or higher than 40 mL/minute prior to MRI. 7. Signed Informed Consent. Exclusion Criteria: 1. Evidence of multi-vessel coronary artery disease likely to require repeat PCI or coronary artery bypass grafting within 4 months. 2. Pulmonary oedema or cardiogenic shock requiring intubation or mechanical support at the time of the planned baseline MRI. 3. Fitted with a non-MRI-compatible cardiac pacemaker or implantable cardioverter defibrillator, or expected to require such a device within 4 months after randomisation. 4. Terminal illness or malignant disease. 5. Advanced hepatic disease. 6. Diagnosis of severe obesity which precludes MRI assessments. 7. Claustrophobia. 8. Acute systemic infection or fever. 9. Anemia (where hemoglobin levels are <10 g/dL), thrombocytopenia (platelet count <100000/µL) or coagulopathy. 10. History of multiple drug allergies or with a known allergy to the drug class of CXCR4 antagonists. 11. Pregnancy or females of childbearing potential who are not using double contraception 12. Known history of human immunodeficiency virus (HIV) infection, chronic hepatitis B or hepatitis C infection or significant active chronic inflammatory disease that requires immunosuppressive medication or regular systemic corticosteroids. 13. Patients who have participated in any investigational drug or device trial within 30 days prior to signing informed consent. 14. Patients who are unwilling or unable to abide by the study requirements. |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
| Country | Name | City | State |
|---|---|---|---|
| Austria | Medical University of Graz | Graz | |
| Austria | Medical University of Vienna | Vienna | |
| Germany | Kerckhoff-Klinik GmbH | Bad Nauheim | |
| Germany | Charité - Campus Benjamin | Berlin | |
| Germany | Charité - Campus Virchow | Berlin | |
| Germany | Hannover Medical School | Hannover | |
| Hungary | Magyar Honvédség Egészségügyi Központ, Kardiológiai osztály | Budapest | |
| Hungary | Semmelweis University | Budapest | |
| Hungary | DEOEC, Kardiológiai Intézet | Debrecen | |
| Hungary | Kaposi Mór Teaching Hospital | Kaposvár | |
| Hungary | Pécs University | Pecs | |
| Hungary | Zala Megyei Kórház,Kardiológia | Zalaegerszeg | |
| Poland | Hospital John Paul II | Krakow | |
| United Kingdom | Edinburgh Heart Centre Royal Infirmary | Edinburgh | |
| United Kingdom | West of Scotland Regional Heart & Lung Center, Golden Jubilee National Hospital | Glasgow | |
| United Kingdom | University Hospitals of Leicester NHS Trust Glenfield Hospital | Leicester | |
| United Kingdom | King's College Hospital | London |
| Lead Sponsor | Collaborator |
|---|---|
| Polyphor Ltd. |
Austria, Germany, Hungary, Poland, United Kingdom,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Change in LVEF (left ventricular ejection fraction) as determined by MRI | Difference in LVEF from baseline (after STEMI and stent procedure, before infusion of drug or placebo) and after 4 months | 4 months | No |
| Secondary | Additional measures of cardiovascular function | Using MRI the following parameters will also be determined: infarct size, LV volumes, regional LV function. Plasma BNP (brain natriuretic peptide) will also be determined. | 4 months | No |
| Secondary | Mobilization of stem and progenitor cells | Time dependent measurement of stem and progenitor cells during and after infusion of POL6326 | 2 days | No |
| Secondary | Pharmacokinetic outcome | Measurement of plasma concentrations of POL6326 at predose and several time points after infusion. | 2 days | No |
| Secondary | Safety of POL6326 by intravenous infusion | Safety as measured by incidence, type and severity of adverse events (Major Adverse Cardiovascular Events (MACE), Arrhythmia) | 12 months | Yes |